The new head of the Ministry of Health of Uzbekistan instructed to suspend the sale of all Quramax medicines

“According to the results of in-depth quality control of Doc-1 Max and Ambronol preparations, the laboratory for quality control and standardization of medicines revealed a discrepancy between the composition specified in the regulatory document. It has been established that some series of these drugs contain ethylene glycol and diethylene glycol instead of or together with propylene glycol,” the letter says.

In addition, on December 29, a lawsuit was filed with the Tashkent City Court to cancel the registration certificates for these drugs. According to the State Register of Medicines and Medical Devices, Doc-1 Max syrup was registered on February 2, 2017, and then on March 29, 2022, and tablets on December 5, 2017. Ambronol – December 11, 2007 and January 15, 2018.

This is not the first such announcement to suspend drug sales. On December 22, the Ministry of Health reported that the sale of Doc-1 Max had been suspended.

On December 29, the former director of the Pharmaceutical Industry Development Agency under the Ministry of Health, Sardor Kariev, ordered wholesale organizations involved in the sale of medicines to suspend the sale of Ambronol cough syrup produced by Marion Biotech and recall it from pharmacies.

On December 30, the press secretary of the agency, Kizlarkhon Begmatova, stated that since December 30, the sale of all medicines to the Indian Marion Biotech has been suspended in Uzbekistan. Among them are Cinepar, Travamax, Ambronol and others.

On specialized websites, there were notes on the ban on the sale of these drugs.

“Gazeta.uz” called four random pharmacies in Tashkent, Bukhara and Khorezm regions, where they announced the absence of medicines imported by Quramax, or their ban on sale.

Earlier it was reported that India suspended the registration certificate of Marion Biotech. The Pharmaceutical Agency of Uzbekistan informed the Indian Embassy in Tashkent that the level of ethylene glycol in the composition of “Doc-1 Max” exceeded the norm by 300 times.